HOVON HO41

Archived

Main info

Identifier:
HOVON 41 AL Amyloidosis
Sponsor:
HOVON
Included patients:
70
Active sites:
13
(of 13)
Title:

Autologous Stem Cell Transplantation for Patients with AL Amyloidosis: A Prospective Phase II Study.

Timeline

Scheduled
Actual
2002
04 Sep
Activated
2006
31 Jan
CloseoutInProgressLastPtOutActualStart
2016
31 Jan
Archived

Flow

Flow

Details

Phase:
Prospective Phase II study
Monitoring Type:
Objectives:

Eligibility

Inclusion Criteria:
  • Age under 66 years
  • MGUS, multiple myeloma stage I
  • Histologically documented systemic AL amyloidosis (see appendix C)
  • Untreated or previously treated with maximal 3 courses of melphalan and prednisone
  • The patient must give informed consent according to the rules of the hospital.
Exclusion Criteria:
  • Prior malignancies diagnosed less than 5 years ago, except non-melanoma skin tumours or stage 0 (in situ) cervical carcinoma. Note: Prior malignancies diagnosed and treated longer than 5 years ago, and in which case it is likely that the patient is cured, are no exclusion criteria.
  • Patients with familial variants of systemic amyloidosis.
  • Severe pulmonary, neurologic, psychiatric, cardiac, liver or metabolic disease not related to AL amyloidosis.

Participating Sites

Site
13 results
Order by
Accrual rate
Activation date
NL-Utrecht-UMCUTRECHT
11
NL-Amsterdam-VUMC
10
NL-Maastricht-MUMC
9
NL-Rotterdam-ERASMUSMC
8
NL-Nijmegen-RADBOUDUMC
8
BE-Leuven-UZLEUVEN
8
NL-Groningen-UMCG
7
NL-Den Haag-HAGA
4
NL-Leiden-LUMC
2
NL-Amsterdam-AMC
2
NL-Nieuwegein-ANTONIUS
1
NL-Amersfoort-MEANDERMC
NL-Apeldoorn-GELREAPELDOORN
= Active hospitals
= Inactive hospitals

Participating Parties

Downloads

Up